Radiprodil is under clinical development by Neurvati Neurosciences and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase I drugs for Neurodegenerative Diseases have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Radiprodil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Radiprodil overview

Radiprodil is under development for the treatment of GRIN-related disorder. It acts by targeting NMDA-2B receptor. It is administered in the from of granules and suspension through oral route.

Neurvati Neurosciences overview

Neurvati Neurosciences is involved in neuroscience product development and treatment options. Neurvati Neurosciences is headquartered in Wilmington, Delaware, the US.

For a complete picture of Radiprodil’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.